Delving into the Latest Updates on Pregabalin with Synapse

Overview

Basic Info

SummaryPregabalin, commonly referred to as Lyrica®, is a well-known anticonvulsant medication, which has found its footing in the treatment of various medical conditions. Such conditions include but are not limited to anxiety disorders, epilepsy, and neuralgia. The mechanism of action that characterizes pregabalin's utility involves blocking the CACNA2D1 and CACNA2D2 calcium channels, thus effectively targeting these disorders with aplomb. The Upjohn Co. received approval for the medical use of pregabalin in the European Union as far back as 2004, indicating that the medication has been a key feature of medical treatment for some time. Pregabalin's indications primarily target the treatment of neuropathic pain conditions, including fibromyalgia, and partial onset seizures in combination with other anticonvulsant medications. These conditions are managed with pregabalin due to its efficacy in minimizing their attendant symptoms. Pregabalin, therefore, serves as a vital tool in the management of chronic pain and neurological disorders.

Drug Type

Small molecule drug

Synonyms

LYRICA CR

+ [10]

Target

CACNA2D1 x CACNA2D2

Action

blockers

Mechanism

CACNA2D1 blockers(Voltage-gated calcium channel alpha2/delta subunit 1 blockers), CACNA2D2 blockers(Voltage-gated calcium channel alpha2/delta subunit 2 blockers)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesEndocrinology and Metabolic Disease+ [2]

Active Indication

FibromyalgiaSeizuresNeuralgia, Postherpetic+ [7]

Inactive Indication

Acute herpes zoster neuropathyBreast CancerComplex Regional Pain Syndromes+ [30]

Originator Organization

The Upjohn Co.

Active Organization

Pfizer Inc.Huizhi Pharmaceutical (Dalian) Co., Ltd.Viatris Ltd. (New Zealand)

+ [15]

Inactive Organization

Viatris, Inc.MyLan SAS

John Hunter Hospital

+ [6]

Drug Highest PhaseApproved

First Approval Date

European Union (05 Jul 2004),

Epilepsies, PartialEpilepsyGeneralized anxiety disorder+ [1]

RegulationSpecial Review Project (China), Priority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC8H17NO2

InChIKeyAYXYPKUFHZROOJ-ZETCQYMHSA-N

CAS Registry148553-50-8

The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy.
The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change (PGIC).
This study is a 3-period cross-over trial. This means researchers will compare 3 different drugs (pregabalin, duloxetine, and placebo) over a period of 19 weeks.
Participants will:
* Undergo a quantitative sensory testing (QST) exam.
* Provide a blood sample.
* Complete questionnaires on the computer.
* Take the study drug as instructed.

Start Date01 Sep 2025

Sponsor / Collaborator

University of Rochester

[+1]

NCT06150898

/ Not yet recruitingPhase 2IIT

Unravelling the Local and Systemic Effects of Primary Surgery and Perioperative Use of Ketorolac and Pregabalin in Primary Breast Cancer Patients According to Adiposity

Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer.
To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug.
Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs

Start Date01 Apr 2025

Sponsor / Collaborator

Jules Bordet Institute

[+1]

ACTRN12624001359527

/ Not yet recruitingPhase 3IIT

A Phase III double-blind placebo-controlled randomised controlled trial to evaluate effectiveness of early treatment with pregabalin in the development of chronic pain in adults with acute whiplash injury

Start Date24 Feb 2025

Sponsor / Collaborator

The University of Queensland

100 Clinical Results associated with Pregabalin

Login to view more data

100 Translational Medicine associated with Pregabalin

Login to view more data

100 Patents (Medical) associated with Pregabalin

Login to view more data

6,528

Literatures (Medical) associated with Pregabalin

01 Jun 2025·Current Neuropharmacology

Vortioxetine versus SSRI/SNRI with Pregabalin Augmentation in Treatment-Resistant Burning Mouth Syndrome: A Prospective Clinical Trial

Article

Author: Adamo, Daniela ; Marenzi, Gaetano ; Leuci, Stefania ; Albert, Umberto ; D’Aniello, Luca ; Coppola, Noemi ; Ottaviani, Giulia ; Mignogna, Michele Davide ; Rupel, Katia ; Aria, Massimo ; Canfora, Federica ; Pellegrini, Luca ; Pecoraro, Giuseppe

Objectives:The treatment of Burning Mouth Syndrome (BMS) represents a challenge in tailoring appropriate medication for individual patients. The augmentation of pregabalin to conventional treatment has shown promising outcomes in relieving pain and improving the quality of life in chronic pain conditions. This study aimed to compare the efficacy of vortioxetine with other antidepressants (SSRIs/SNRIs) in combination with pregabalin in a cohort of unresponsive BMS patients and to predict treatment response by using clinical data.Methods:A 52-week randomized, open-label, comparative clinical study was conducted, enrolling 203 BMS patients previously treated with one antidepressant for 12 weeks and non-responders to the treatment (clinical trial registration: NCT06025474). The study sample included two groups: Group A (136) received vortioxetine, while Group B (67) received SSRIs/SNRIs. Pregabalin (75 mg/day) was added to both groups, with a potential dosage increase to 150 mg/day for inadequate responders after 12 weeks. Treatment response was assessed with VAS and SF-MPQ, HAM-A, and HAM-D scores at 12, 24, 36, and 52 weeks. Stepwise logistic regression analysis was used to predict treatment response.Results:A total of 84 (61.8%) BMS patients in Group A and 39 (58.2%) in Group B showed treatment response. Group A reported a faster onset of action compared to Group B (44.8% versus 22.4% at time 1; p:0.002**) and lower adverse event rates (8.8% versus 20.8%; p:0.001).Conclusion:The addition of pregabalin to vortioxetine may be considered a potential treatment option for BMS. Further research is required to corroborate these findings and optimize personalized treatment approaches for BMS patients.

01 Apr 2025·Current Opinion in Obstetrics & Gynecology

Updates in nonhormonal therapy for perimenopausal and menopausal symptoms

Review

Author: Voedisch, Amy J.

Purpose of reviewPerimenopausal and menopausal symptoms are common and may significantly impact quality of life. Menopausal hormone therapy is the most effective treatment but may not be appropriate in all cases. Nonhormonal alternatives range from lifestyle changes and dietary supplements to medical interventions and prescription therapies. This review will summarize the newest advancements in nonhormonal therapies for bothersome perimenopausal and menopausal symptoms.Recent findingsThe Menopause Society recently updated their recommendations and guidelines for nonhormonal therapies. Previous recommendations, such as clonidine and pregabalin, are no longer recommended. A new class of medication, neurokinin B antagonists, are now available to target vasomotor symptoms and show promise in addressing sleep and mood issues.SummaryWell tolerated, effective nonhormonal therapies are available to address perimenopausal and menopausal symptoms for those patients who are not candidates for or chose not to use menopausal hormone therapy.

01 Apr 2025·Journal of Ultrasound in Medicine

Efficacy of Ultrasound‐Guided Transverse Abdominal Plane Block for Residual Pain After Pulsed Radiofrequency in Abdominal Acute/Subacute Herpes Zoster‐Related Pain

Article

Author: Tong, Sheng‐Xiong ; Feng, Dan ; Li, Shao‐Jun

BackgroundPulse radiofrequency (PRF) can reduce the persistent pain of herpes zoster (HZ), but some patients still have residual pain and do not achieve satisfactory results. This study aimed to assess the efficacy of PRF combined with transverse abdominal plane (TAP) block for abdominal acute/subacute HZ‐related pain.MethodsA total of 137 acute/sub‐acute HZ patients with successful PRF treatment were recruited from the Pain Department of Wuhan No. 1 Hospital between January 2018 and January 2020. There were two groups: the transversus abdominis plane group (TAP group, n = 64) and the normal saline group (NS group, n = 60). Pain intensity, sleep quality, and quality of life were quantified using the visual analogue scale (VAS), the five‐item questionnaire and scoring system, and the 36‐item Short Form Health Survey (SF‐36) questionnaire, respectively. Follow‐up assessments were conducted at baseline, 1 day, 3 months, 6 months, and 12 months after the block therapy.ResultsCompared to the NS group, the TAP group showed significantly decreased pain scores 1 day, 3 months, 6 months, and 12 months after block therapy (P < .05). The sleep quality scores were lower in the TAP group than that in the NS group at 6 months (5.0 ± 2.4 vs 6.3 ± 3.7, p = .042), and 12 months after therapy (3.1 ± 1.8 vs 4.1 ± 2.4, p = .031). For quality of life, in comparison to NS group participants, those in the TAP group exhibited significantly higher scores (p < .05) for quality of life at 3 months, 6 months, and 12 months follow‐up. There was a significant decrease in the proportion of pregabalin and analgesic medications in the TAP group and NS group at 6 and 12 months after treatment compared to Baseline (p < .001). Furthermore, the results showed that there was a significant difference in VAS, sleep quality scores (SQS), and quality of life between the PRF + TAP group and pharmacological therapies group before and 12 months after treatment (p < .05).ConclusionThe TAP block is a promising complementary treatment for acute/subacute HZ patients who have undergone PRF treatment. Combining PRF with the TAP block has the potential to alleviate HZ‐related pain, enhance the patients' quality of life, and improve their sleep quality.

71

News (Medical) associated with Pregabalin

07 Mar 2025

·endpts.com

Start of 2025 comes with generic drug price decreases, several major increases, report finds

More generic drug prices decreased than increased in January, a new report from 46Brooklyn found. The report said for every generic drug price increase in January, 1.3 generic drugs saw their price decrease. It’s a trend that 46Brooklyn CEO Antonio Ciaccia called “a largely favorable view.” Even still, three generic drugs saw their prices increase significantly, including the nerve pain drug pregabalin ER 165 mg (26% increase), the nausea drug dronabinol 10 mg (21% increase), and the ADHD drug methylphenidate CD 30 mg (18% increase). For branded drugs, Chiesi’s Ferriprox and Harrow’s Verkazia both increased by more than 20%, although brand-name increases are largely restricted by a Medicaid program that forces pharma companies to pay rebate penalties for drug price increases greater than the rate of inflation. There were 963 net brand price increases in January, according to the report, which was largely in line with the 896 net brand price increases in January 2024 and 986 price increases in January 2023. A previous analysis from Ciaccia’s consultancy firm 3 Axis Advisors anticipated price hikes to more than 1,000 medicines. The report from 46Brooklyn also highlights several key brand-name drug increases that could cost Medicaid significantly more than what they were paying in previous years. For instance, J&J’s Stelara saw a nearly 5% list price increase, which works out to about $1.5 billion in gross prior-year Medicaid expenditures. Several biosimilars to Stelara recently launched at prices as low as 90% off the brand-name price. Chiesi raised the list price of its enzyme replacement therapy Revcovi by 4.5% in January. The report noted that the average gross cost per prescription in Medicaid for this drug is roughly $200,000, which means the list price increase “is anticipated to add roughly $9K in gross cost per prescription. This is the highest added gross cost per Rx for the brand drugs that took price increases in January 2025.” Chiesi did not immediately respond to a request for comment. In addition to the 46Brooklyn report, Sanofi released a report earlier this week on its pricing principles , showing the French company in 2024 spent 36% of its gross sales to payers as rebates. And UCB also released its own pricing report this week showing that 54% of its 2024 gross sales were provided to supply chain stakeholders, including private and public payers as rebates, discounts and fees.

Biosimilar

19 Dec 2024

·www.accesswire.com

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

MIAMI, FL / ACCESSWIRE / December 19, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing therapies for neurological and neuropsychiatric disorders, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Ketamir-2, its novel oral ketamine analog for the treatment of neuropathic pain. The IND submission marks a major step in advancing Mira's lead drug candidate while reflecting its commitment to meeting milestones and timelines.Erez Aminov, Chairman & CEO of Mira, stated: "This IND submission highlights our team's commitment to executing efficiently as we advance transformative therapies. Ketamir-2 not only has demonstrated remarkable potential for neuropathic pain but also offers a broad opportunity across other major neuropsychiatric conditions. We look forward to beginning Phase I trials and continuing to deliver on our mission to address unmet medical needs."The IND application includes comprehensive data and reports detailing Ketamir-2's pharmacology, pharmacokinetics, and toxicology, along with results from both in vitro and in vivo studies, including validated neuropathic pain disease models. In parallel with the submission, the company is preparing to conduct a complementary neurotoxicity study, as required by the FDA's written feedback to the pre-IND documentation.According to a market analysis report from Fortune Business Insights, the neuropathic pain market in North America, including the United States, Canada, and Mexico, is valued at $3.1 billion and is expected to grow at a 6-7% compound annual growth rate (CAGR), reaching $4.5 billion by 2030. Despite this growth, existing treatments remain inadequate. Gabapentin and pregabalin, while widely prescribed, provide limited efficacy and are associated with side effects such as sedation, dizziness, and weight gain. Opioids remain a common treatment option but come with well-known risks of dependency, addiction, and respiratory depression. Intravenous ketamine, though effective for some patients, requires invasive administration and is often associated with psychotropic side effects, including hallucinations and dissociation.Ketamir-2 is specifically designed to address the limitations of existing treatments through its selective targeting of the NMDA receptor. By binding to a specific site on the NMDA receptor with low affinity, Ketamir-2 significantly reduces the risk of psychotropic effects commonly associated with traditional ketamine. Furthermore, it is not a substrate for P-glycoprotein (P-gp), which allows for better oral absorption and enhanced blood-brain barrier penetration. Unlike traditional ketamine, Ketamir-2 does not cause sedation or hyperactivity-side effects often linked to psychiatric conditions such as schizophrenia, bipolar mania, and ADHD. As a non-opioid therapy, Ketamir-2 is designed to eliminate the risks of dependency and addiction. Additionally, the DEA has determined that Ketamir-2 is not a controlled substance, streamlining accessibility and minimizing regulatory hurdles.Preclinical studies have demonstrated Ketamir-2's ability to achieve 100% pain reversal, fully normalizing pain thresholds in validated neuropathic pain models. Furthermore, Ketamir-2 has shown a strong safety and toxicological profile, observed across cardiovascular, CNS, respiratory, or toxicology assessments.Dr. Itzchak Angel, Chief Scientific Advisor at Mira, commented: "Ketamir-2's selective mechanism of action, strong safety profile, and ability to achieve full pain reversal underscore its potential as a transformative therapy."With the IND submitted, MIRA expects to initiate Phase I Clinical Trials in Q1 2025 to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers. Phase IIa trials are expected to follow in late 2025 to assess efficacy in neuropathic pain patients. Beyond neuropathic pain, the company is exploring additional indications for Ketamir-2, including MDD, MDD-SI, TRD and PTSD.About MIRA Pharmaceuticals, Inc.MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. MIRA holds the exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a novel, patent-pending oral ketamine analog under investigation to treat neuropathic pain (NP), treatment-resistant depression (TRD), major depressive disorder with suicidal ideation (MDD-SI), and post-traumatic stress disorder (PTSD).MIRA's novel oral pharmaceutical marijuana analog, MIRA-55, is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. If approved by the FDA, MIRA-55 could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders.The U.S. Drug Enforcement Administration's scientific review concluded that both Ketamir-2 and MIRA-55 would not be considered controlled substances or listed chemicals under the Controlled Substances Act and its governing regulations.Additional information about MIRA Pharmaceuticals is available at www.mirapharmaceuticals.com.Cautionary Note Regarding Forward-Looking StatementsThis press release and the statements of MIRA Pharmaceuticals' (or the "Company") management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. These forward-looking statements include, without limitation, statements regarding the anticipated benefits of the study results described herein as well as the timing for the Company's other preclinical studies and the filing of an IND for Ketamir-2. Any forward-looking statements in this press release are based on the Company's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning the Company's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2023, and other SEC filings, which are on file with the SEC at www.sec.gov and the Company's website at https://www.mirapharmaceuticals.com/investors/sec-filings. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.Contact InformationHelga Moya [email protected](786) 432-9792SOURCE: Mira Pharmaceuticals, Inc.

Phase 1Phase 2IND

02 Dec 2024

·www.drugs.com

Guidelines Developed for Treatment of Restless Legs Syndrome

MONDAY, Dec. 2, 2024 -- In a clinical practice guideline issued by the American Academy of Sleep Medicine and published online Sept. 26 in the Journal of Clinical Sleep Medicine , recommendations are presented for the treatment of restless legs syndrome (RLS). John W. Winkelman, M.D., Ph.D., from Massachusetts General Hospital in Boston, and colleagues developed recommendations for treatment of RLS and periodic limb movement disorder in adults and pediatric patients. The researchers developed three good practice statements that were based on expert consensus. They recommend all clinicians should regularly test serum iron studies, including ferritin and transferrin saturation, in all patients with clinically significant RLS, ideally in the morning; analysis of these studies influences the decision to use oral or intravenous (IV) iron treatment. The authors also state that addressing exacerbating factors, including alcohol, caffeine, antihistaminergic, serotonergic, and anti-dopaminergic medications, should be the first step in RLS management. They note RLS is common in pregnancy and the pregnancy-specific safety profile of each treatment should be considered. Recommendations for adults with RLS include use of gabapentin enacarbil over no gabapentin enacarbil; use of gabapentin over no gabapentin; use of pregabalin over no pregabalin; and use of IV ferric carboxymaltose over no IV ferric carboxymaltose for those with appropriate iron status (strong recommendations; moderate certainty of evidence). In addition, there is a strong recommendation against use of cabergoline. "Guided by the best evidence in the scientific literature, we've provided recommendations that will improve the ability of clinicians to provide patient-centered care for people who have RLS," Winkelman said in a statement. One author disclosed ties to the pharmaceutical and medical device industries. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

100 Deals associated with Pregabalin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02716	Pregabalin	N03AX16	DB00230

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Fibromyalgia	United States	Upjohn US 2 LLC	21 Jun 2007
Seizures	Australia	Viatris Pty Ltd.	13 Apr 2005
Neuralgia, Postherpetic	United States	CP Pharmaceuticals Ltd.	30 Dec 2004
Epilepsies, Partial	Norway	Upjohn EESV	05 Jul 2004
Epilepsies, Partial	Iceland	Upjohn EESV	05 Jul 2004
Epilepsies, Partial	European Union	Upjohn EESV	05 Jul 2004
Epilepsies, Partial	Liechtenstein	Upjohn EESV	05 Jul 2004
Epilepsy	Iceland	Upjohn EESV	05 Jul 2004
Epilepsy	Liechtenstein	Upjohn EESV	05 Jul 2004
Epilepsy	European Union	Upjohn EESV	05 Jul 2004
Epilepsy	Norway	Upjohn EESV	05 Jul 2004
Generalized anxiety disorder	Liechtenstein	Upjohn EESV	05 Jul 2004
Generalized anxiety disorder	Iceland	Upjohn EESV	05 Jul 2004
Generalized anxiety disorder	European Union	Upjohn EESV	05 Jul 2004
Generalized anxiety disorder	Norway	Upjohn EESV	05 Jul 2004
Neuralgia	Liechtenstein	Upjohn EESV	05 Jul 2004
Neuralgia	Norway	Upjohn EESV	05 Jul 2004
Neuralgia	Iceland	Upjohn EESV	05 Jul 2004
Neuralgia	European Union	Upjohn EESV	05 Jul 2004

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Generalized anxiety disorder	Discovery	Iceland	MyLan SAS	25 Jun 2015
Generalized anxiety disorder	Discovery	Liechtenstein	MyLan SAS	25 Jun 2015
Generalized anxiety disorder	Discovery	Norway	MyLan SAS	25 Jun 2015
Diabetic peripheral neuropathy	Discovery	United States	Pfizer Inc.	30 Dec 2004
Neuralgia, Postherpetic	Discovery	United States	Pfizer Inc.	30 Dec 2004

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05974501 (CTgov)	Phase 4	complications of arthroplasty \| Osteoarthritis, Knee \| Pain, Postoperative	84	Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Celebrex+Dexamethasone+Meloxicam (Preoperative Adductor Canal Block Group)	ktxhphizyn(rjdhozomza) = hbhqqbvatc wbjnnkxbut (vdwfddmgid, ykrevxjpun - mfcrlbkbbk) View more	-	12 Feb 2025
				Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Celebrex+Dexamethasone+Meloxicam (Postoperative Adductor Canal Block Group)	ktxhphizyn(rjdhozomza) = owlfvlrknx wbjnnkxbut (vdwfddmgid, snzdglmkrm - hqigfvwdwo) View more
NCT04122196 (CTgov)	Phase 2/3	Kidney Calculi \| Pain, Postoperative	118	Pregabalin 300mg (Pregabalin 300mg)	ymyxqlcvyo(olbktzzsbv) = bbftbxkhnv lymqqjzlss (guzqcthkcz, ftpcfcigxg - nolzkvystl) View more	-	24 Oct 2024
				Placebo oral tablet (Placebo)	ymyxqlcvyo(olbktzzsbv) = snhvlzantw lymqqjzlss (guzqcthkcz, iwnnypvzmm - vvzfwjytmv) View more
NCT04015908 (CTgov)	Phase 4	-	100	Pregabalin+Acetaminophen+Celecoxib+Oxycodone (Multi-modal)	wqkjxvyucl(fzneclortk) = iqaoqlblzi oqmegxcbnt (udganeuxrf, oanftirqmf - nvahocoawn) View more	-	08 Jul 2024
				Percocet (Control)	wqkjxvyucl(fzneclortk) = nozwyykclv oqmegxcbnt (udganeuxrf, bhnawuwjxl - sginmoczaw) View more
NCT04218240 (PGB-LOF, CTgov)	Phase 2	Opioid abuse	90	Pregabalin 200 MG capsules+Lofexidine 0.18Mg Tab (PGB/LFX;)	ygaoyxyhfp(yfaoblevmn) = nuqtthcgcz asjjwfmkfr (ukjkchnkuh, xbeqknogow - bngylmlsoi) View more	-	20 May 2024
				Placebo oral tablet+Lofexidine 0.18Mg Tab (Lofexidine and PLACEBO)	ygaoyxyhfp(yfaoblevmn) = lgccgfxmht asjjwfmkfr (ukjkchnkuh, wkpcyhehna - giywoozece) View more
NCT02884908 (CTgov)	Phase 3	Alcohol Use Disorder \| Stress Disorders, Post-Traumatic	57	BBCET+Pregabalin (Pregabalin + BBCET)	dmcgywyeqp(pvnmgktstm) = pqgxbeltyn hxtmaulorg (mzeoyibqlb, aeniwycpsf - tvriutmesz) View more	-	13 Mar 2024
				Placebo (Placebo + BBCET)	dmcgywyeqp(pvnmgktstm) = yuhiupmsut hxtmaulorg (mzeoyibqlb, oechaubxkl - jdcgjwsigm) View more
ESMO_ASIA2023	Not Applicable	Add-on	84	Olanzapine 5 mg plus pregabalin 75 mg	vnqoipdwxg(blhejlbuhd) = gbcbygivfg vccxhufgll (dyacgjptsj )	-	02 Dec 2023
				Placebo	vnqoipdwxg(blhejlbuhd) = phdyixrjxs vccxhufgll (dyacgjptsj )
NCT00310765 (CTgov)	Phase 4	Abdominal Pain \| Tissue Adhesions \| Surgical Adhesion	18	pregabalin+placebo (Patients Treated With Placebo)	bfjkpkgfma(gmkhbtotjf) = syqocfgylj dxdtixlazn (ztlajadwzg, dreqzpxbga - czvasamakn) View more	-	23 Oct 2023
				Pregabalin (Patients Treated With Pregabalin)	bfjkpkgfma(gmkhbtotjf) = rlbnllpoxx dxdtixlazn (ztlajadwzg, korodhaxor - jrnrwfthts) View more
NCT04246619 (BLOSSOM, Pubmed)	Phase 4	Diabetic peripheral neuropathic pain	254	Pregabalin	(jxgfxeqnlt) = jbjzvxreig pbfsaabocp (gfrrrltdfn, [ - 41.4, to 32.6]) View more	Positive	18 Jul 2023
				Duloxetine	(jxgfxeqnlt) = hhjcahpvlv pbfsaabocp (gfrrrltdfn, [ - 41.5, to 32.3]) View more
EULAR2023	Not Applicable	Cancer Pain	-	Pregabalin	vfrdbkxnac(wikgsyxdae) = ywnorimbwy qivqkkvmxt (fqdfpglugj )	Negative	31 May 2023
				Gabapentin	vfrdbkxnac(wikgsyxdae) = bivacnmxij qivqkkvmxt (fqdfpglugj )
NCT01801189 (CTgov)	Phase 4	Pain, Postoperative	61	pregabalin (Pregabalin)	goloqswdvw(wnrlrdosyq) = mxvknzxhhe zyqteavmgb (dyyyezkfpo, ltysoiloro - nlmsmtjype) View more	-	06 Jun 2022
				Placebo (for Pregabalin) (Sugar Pill)	goloqswdvw(wnrlrdosyq) = cpoykgovxb zyqteavmgb (dyyyezkfpo, roimghvpet - jqwtfcoqyv) View more